Preparing market rhythm analysis...
News Center
Browse cached source articles used by the rhythm engine. Filter by ticker, sentiment, or keyword, then open the stock rhythm page for deeper daily, swing, and long-term analysis.
Cached Articles
32987
Tickers With News
515
Showing Now
49
Top Ticker
AAPL
Featured Tickers
Jump straight into the most important tickers for testing and market coverage.
Latest Articles
Amplitude Therapeutics, a biotechnology company developing trans-amplifying RNA (taRNA) medicines and vaccines, today announced a strategic research collaboration and licensing agreement with Eli Lilly and Company
Bryn Talkington picked Horizon Kinetics, Stephanie Link chose Elanco Animal Health, and Jason Snipe recommended Netflix.
OmniAb (OABI) analysis: platform scaling via Eli Lilly partnership, milestone-rich revenue outlook, 2026 cash guidance, valuation and catalystsâread now.
- Reuters
The therapeutic target and modality are undisclosed.
The OmniAb Lilly Deal offers up to $370 million in milestones as OABI raises its 2026 cash outlook and shares jump premarket
Eli Lilly’s second quarter was marked by a positive market reaction, despite the company missing Wall Street’s revenue expectations. Management credited growth in key products—especially in cardiometabolic health, oncology, and neuroscience—as drivers of performance. CEO David Ricks pointed to “robust revenue growth across all Key Products and major geographies,” noting the strength of new medicines and expansion in emerging markets. The launch of Foundayo in the U.S. and UAE, along with ongoing
Eli Lilly's shares are near a record high as the company files six lawsuits against alleged illegal sales of its experimental obesity drug, retatrutide. These legal actions aim to protect the drug's future market ahead of its planned U.S. submission in Q1 2027, given its strong Phase 3 efficacy data. The lawsuits are a proactive measure to safeguard its next major franchise, as current revenue drivers Mounjaro and Zepbound already contribute significantly to Lilly's earnings.
The stock continues to look unstoppable.
Eli Lilly (LLY) has spent 2026 defending its lead in the weight-loss drug market, mostly with injections. That approach is changing. On Aug. 10, Britain's medicines regulator cleared Lilly's new daily pill for both weight management and type 2 diabetes. It was the first approval the drug received ...
Lilly is suing several US companies that are allegedly selling illegal versions of its weight loss candidate, retatrutide.
NVO's GLP-1 pills offer fresh momentum, but Eli Lilly's fast-growing injectable and oral therapies threaten to widen the competitive gap.
Lilly's Foundayo records $98M in Q2 sales, while rising prescriptions, broader access and global expansion set the stage for H2 growth
Revenue surged 48% on Mounjaro and Zepbound demand, with full-year guidance raised.
Novo Nordisk's CEO conceded Eli Lilly is gaining market share even as oral Wegovy hits record prescriptions and the stock keeps falling.
A marketing dispute could reshape a crucial competitive advantage
Eli Lilly filed six lawsuits against U.S. entities for illegally selling unapproved retatrutide, warning consumers of serious health risks.
Ahead of an approval filing, the drugmaker is amping up a fight against sellers who claim to offer versions of its highly anticipated “triple-G” weight loss medicine.
Eli Lilly has filed six lawsuits against US companies for allegedly selling unauthorized versions of its experimental obesity drug, retatrutide. The drugmaker emphasizes that retatrutide has not received FDA approval and carries significant risks. This action is part of Lilly's broader effort to combat copycat versions of its GLP-1 products, which are known for their benefits beyond diabetes, including effects on heart, kidney, sleep apnea, and addiction.
Absci (ABSI) is back in focus after releasing early Phase 1 data for its lead antibody ABS-201 and securing a US$40 million investment and development support from Eli Lilly tied to the program. See our latest analysis for Absci. Absci’s recent early Phase 1 ABS-201 update and Eli Lilly’s US$40 million commitment arrive after a sharp run, with the share price delivering a 77.55% 90 day return and a 160.66% year to date share price return, alongside a very large 3 year total shareholder...
Absci Corporation recently reported second-quarter 2026 results showing a net loss of US$33.21 million, wider than a year ago, while basic and diluted loss per share from continuing operations narrowed to US$0.21. Alongside these figures, Absci highlighted encouraging early Phase 1 data for ABS-201, its prolactin receptor antibody, and a US$40 million investment and development support from Eli Lilly that extend its cash runway into the second half of 2028. Next, we’ll examine how Eli...
Eli Lilly (LLY) shows a strong technical breakout setup with a 10/10 rating, tight consolidation, and defined support/resistance levels.
Obesity-drug giant Eli Lilly stock is approaching a new buy point as the ongoing stock market rally strengthens.
Lilly said the products being sold on the black market are unverified, unapproved, and not worth the risk.
The company has referred more than 200 sellers and individuals to regulators.
Lilly is trying to protect an experimental obesity medicine from unauthorized sellers before regulators decide whether to approve it.
Eli Lilly and Company (NYSE: LLY) today escalated its continued fight to protect patients from the dangerous black market for retatrutide, filing six new lawsuits against U.S. entities selling black-market products in addition to having referred hundreds of bad actors to regulators and law enforcement worldwide. Lilly is also calling on the entities that sellers use to conduct their illegal business—social media and e-commerce platforms, credit card companies, payment processors and shipping and
Novo Nordisk is playing catch-up in the GLP-1 race.
I Underestimated Eli Lilly: Retatrutide Changes The Risk/Reward (Rating Upgrade)
Wegovy pill upside has already played out, leaving the multiple at the European pharma average
Novo Nordisk CEO Mike Doustdar defended the company's lawsuit against Eli Lilly, asserting that competition must be fair and patients deserve full transparency regarding weight-loss drug efficacy. The lawsuit alleges Lilly's advertising for its GLP-1 drugs misleads consumers by comparing them to an older, lower-dose version of Novo's Wegovy. Doustdar highlighted the newer 7.2 mg Wegovy, which shows comparable weight loss to Lilly's Zepbound, and touted the success of the new Wegovy pill launch.
Jeff Marks and Jim Cramer say Eli Lilly's GLP-1 stock rally has years left, backed by surging global demand.
Lilly's Foundayo wins U.K. approval, taking its weight-loss pill battle with Novo Nordisk's Wegovy beyond the U.S. market.
One of its more popular products just got the green light from a major national regulator.
The obesity-drug market has largely been viewed as a race between clinical innovation and commercial execution. Investors have spent the past three years comparing prescription growth, market share, and pipeline candidates as Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) compete for dominance in one of healthcare’s fastest-growing markets. Yet another competitive advantage for investors to […]
For years, investors have viewed Eli Lilly (NYSE:LLY) and Novo Nordisk (NYSE:NVO) through one lens: the race to dominate the booming obesity-drug market. But Washington is beginning to shift the conversation. With the U.S. government pushing pharmaceutical companies to manufacture more medicines domestically and reduce dependence on overseas supply chains, manufacturing has become more of […]
Foundayo secured its first European authorization, extending Lilly's obesity portfolio beyond injectable medicines
Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.
During the August 6 episode of CNBC’s Mad Money, Jim Cramer pointed to a growing sector rotation as portfolio managers look for innovation outside the mega-cap technology space. He said: Finally, tech had such a run that portfolio managers want exposure to other sectors of the market that still have innovation. Think of them as […]
Eli Lilly’s updated fair value price target has shifted from US$1,270.37 to US$1,297.31, giving investors a fresh reference point for how analysts are framing the stock today. Much of this reset is tied to recent Street commentary that focuses on incretin and GLP-1 therapies, Q2 results, and the potential of assets like Mounjaro, Zepbound, retatrutide and Foundayo. As you read on, you will see how to track these moving parts and keep up with the evolving Eli Lilly narrative. Stay updated as...
Eli Lilly (NYSE:LLY) delivered a quarter that forced Wall Street to catch up to its own numbers. On August 5, the company reported second-quarter revenue of $23.0 billion, up 48% from a year earlier, and used the momentum to raise its full-year sales and profit targets. Shares moved higher the same day as investors focused […]
Eli Lilly and Company (NYSE:LLY) reported 48% revenue growth in the second quarter of 2026, driven primarily by continued demand for its cardiometabolic medicines MOUNJARO and ZEPBOUND, while raising its full-year revenue and earnings guidance. Chair and CEO Dave Ricks said the company delivered gr
Global pharmaceutical company Eli Lilly (NYSE:LLY) reported Q2 CY2026 results topping the market’s revenue expectations, with sales up 47.7% year on year to $22.97 billion. The company’s full-year revenue guidance of $86 billion at the midpoint came in 0.6% above analysts’ estimates. Its non-GAAP profit of $8.38 per share was 27.3% above analysts’ consensus estimates.
Eli Lilly (NYSE: LLY) reported that its KRAS G12C inhibitor olomorasib received FDA Breakthrough Therapy designation for advanced pancreatic cancer in patients with a KRAS G12C mutation. The company entered a new clinical trial collaboration with Amplia Therapeutics to test olomorasib in combination with Amplia's FAK inhibitor narmafotinib in advanced non small cell lung cancer. These developments highlight Eli Lilly's efforts to broaden its oncology portfolio beyond its diabetes and obesity...
Eli Lilly (LLY) posted a second-quarter result strong enough to shift the debate around its stock. For months, the debate centered on one worry: a slow start for its new obesity pill. That worry did not disappear in the second quarter, but it stopped driving the conversation. Bank of America came ...
It's not much of a rivalry yet.
Eli Lilly Q2 2026 surged on Mounjaro/Zepbound; guidance raised to $85â$87B as the pipeline expands. Click here for this latest update.
If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.
Can anyone take the top spot away from Eli Lilly in the anti-obesity area?
